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Chapter

Amino Acids Profiling for the
Diagnosis of Metabolic Disorders
Yana Sandlers

Abstract
Inborn errors of metabolism (IEM) represent a group of inherited diseases in
which genetic defect leads to the block on a metabolic pathway, resulting in a single
enzyme dysfunction. As a downstream consequence of the residual or full loss of the
enzymatic activity, there is an accumulation of toxic metabolites in the proximity of
the metabolic block and/or a deficiency of an essential metabolic product which leads
to the clinical presentation of the disease. While individually IEMs are rare, a collectively estimated incidence of metabolic inherited disorders is 1:800. The genetic basis
of IEMs can involve abnormalities such as point mutations, deletions or insertions,
or more complex genomic rearrangements. Categorization of IEM can be simply
made on the basis of the affected metabolic network: fatty acids oxidation disorders,
protein/amino acids metabolism disorders, disorders of carbohydrate metabolism,
lysosomal storage diseases, peroxisomal disorders, and mitochondrial diseases. This
chapter will overview amino acid metabolism-related inherited disorders and amino
acid analysis for the diagnosis and routine monitoring of this category of IEMs.
Keywords: inborn error of metabolism, amino acids disorders, quantitative amino
acids analysis, ion exchange chromatography, mass spectrometry

1. Introduction
Amino acids (Figure 1) play multiple important roles in our body: they are basic
structural protein units and precursors of neurotransmitters, porphyrins, and nitric
oxide. Furthermore, amino acids derived from the dietary proteins serve as energy
source since while catabolized in our body, amino acids form organic acids that can
replenish Krebs cycle and ammonia that eliminates through urea cycle [1].
Amino acids disorders (also called aminoacidopathies) are a group of inborn
errors of metabolism diseases, caused by the inherited defects in pathways involved
in amino acids metabolism. All primary amino acids disorders (Table 1) follow an
autosomal recessive mode of inheritance which means that the mutation caused
a metabolic block is present in the genetic material of both parents. As a result of
mutation, the inherited defect is reflected downstream as a lack or a partial biological activity of enzymes involved in amino acids metabolism. Consequently, some
substrates in these pathways accumulate or are diverted into alternative pathways.
Therefore, amino acids disorders are biochemically characterized by abnormal
levels of single or several amino acids and their downstream plasma and/or urine
metabolites (Tables 2–6). Amino acid disorders are presented with variable and
often nonspecific clinical symptoms. In conjunction with medical support, these
disorders are managed by nutritional restrictions, supplements and medical
1
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Figure 1.
The general structure of amino acids consist of an amino group, a carboxylic group and a variable R side chain
that has a major effect on solubility and polarity.

foods that limit consumption of an offending amino acid or in some cases protein
consumption. It is important therefore routinely perform amino acids’ analysis to
monitor dietary treatment outcomes in already diagnosed individuals. In the next
chapters, primary amino acids disorders are reviewed and quantitative amino acid
analysis in clinical settings is discussed.
1.1 Phenylketonuria
Phenylketonuria (commonly known as PKU, incidence 1 in 13,500–19,000 births
in the United States [2]) is an inherited disorder of phenylalanine metabolism characterized by phenylalanine hydroxylase deficiency (Figure 1). The enzyme catalyzes the
conversion of phenylalanine to tyrosine in the presence of tetrahydrobiopterin (BH4)
as a cofactor. Based on plasma phenylalanine level, PKU is categorized by severe
(Phe > 1200 μmol/L), mild (Phe = 600–1200 μmol/L) and hyperphenylalaninemia
(above the normal cut off but below 600 μmol/L) phenotypes. Clinically PKU can be
presented with growth failure, global developmental delay, severe intellectual disabilities and other severe symptoms. During pregnancy, elevated levels of phenylalanine
have teratogenic effects on the developing fetus [3] and the condition is recognized
as maternal PKU. Phenylalanine accumulation is also seen in defects of biopterin
cofactor biosynthesis and regeneration [4] (Table 1). Nutritional management of
PKU targets excessive accumulation of phenylalanine by restriction of natural protein
intake in combination with the use of phenylalanine-free protein substitutes.
1.2 Disorders of tyrosine metabolism
Tyrosine metabolic pathway consists of five enzymatic reactions taking place
mainly in hepatocytes and renal proximal tubules. Tyrosinemia I is the most severe
inherited disorder of tyrosine metabolism caused by a deficiency of fumarylacetoacetate hydrolase, the last enzyme in the tyrosine catabolic pathway. The disorder
has a high incidence in French Canadian ethnicity [5] and involves hepatorenal
dysfunction. Tyrosinemia II is caused by a deficiency of the hepatic tyrosine
aminotransferase and manifested by mental retardation and other severe symptoms
[6]. A deficiency in the activity of 4-hydroxyphenylpyruvate dioxygenase leads to
tyrosinemia III, a rare disorder characterized by mild mental retardation and/or
convulsions [7, 8]. All three disorders biochemically characterized by high levels of
plasma tyrosine (hypertyrosinemia) and urine excretion of downstream tyrosine
metabolites (Table 1). Elevated plasma tyrosine can also be seen due to vitamin-C
responsive transient tyrosinemia during the neonatal period (Figure 2).
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Aromatic amino acids disorders
Disorder name

Amino acid
involved

Enzyme or
transport
defect

Additional biomarkers

PKU classical

Phe (B) high

PAH

Phe: Tyr ratio (B), phenylpyruvic, phenyllactic
and 2-hydroxyphenylacetic acids (U)

Defect of
biopterin cofactor
biosynthesis

Phe (B) high

GTPCH

Low biopterin, neopterin (U)

Defect of
biopterin cofactor
biosynthesis

Phe (B) high

PTPS

Low biopterin, high neopterin (U)

Defect of
biopterin cofactor
regeneration

Phe (B) high

PCBD1

High neopterin and primapterin (U)

Defect of
biopterin cofactor
regeneration

Phe (B) high

DHPR

High biopterin (U) and low DHPR activity in
dried blood spots

Tyrosinemia I

Tyr (B) high

FAH

Succinylacetone (DBS, U), 4-hydroxyphenylpyruvic, 4-hydroxy-phenyllactic acids
(U)

Tyrosinemia II

Tyr (B) high

TAT

4-hydroxyphenylpyruvic, 4-hydroxyphenyllactic acids (U)

Tyrosinemia III

Tyr (B) high

HPPD

4-hydroxyphenylpyruvic,
4-hydroxyphenyllactic acids (U)

PAH, phenylalanine hydroxylase; GTPCH, GTP cyclohydrolase; PTPS, 6-pyrovoyltetrahydropterin synthase; PCBD1,
pterin-4a-carbinolamine dehydratase; DHPR, dihydropterin reductase; FAH, fumarylacetoacetate hydrolase; TAT,
tyrosine aminotransferase; HPPD, 4-hydroxyphenylpyruvate dioxygenase.

Table 1.
Laboratory findings in aromatic amino acids disorders.

Figure 2.
Reaction catalyzed by phenylalanine hydroxylase. Tetrahydrobiopterin (BH4) is a co-factor of PAH. DHPR,
dihydropteridine reductase; PCBD1, pterin-4-α-carbinolamine dehydratase.
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1.3 Maple syrup urine disease
Maple syrup urine disease is a disorder of branch chain amino acids metabolism
caused by a deficiency of branched-chain α-keto acid dehydrogenase complex.
MSUD is presented with five clinical phenotypes on the basis of the age at onset, the
severity of symptoms and response to thiamine supplementation [9]. MSUD characterized biochemically by elevated plasma branched-chain amino acids (leucine,
isoleucine, valine, allo-isoleucine) and their abnormal ratio (normal ratio is valine:is
oleucine:leucine/3.5:1:2). The disease is managed by dietary leucine restriction, thus
all branch chain amino acids and allo-isoleucine are routinely monitored. The classic
MSUD is the most severe form of the disease characterized by no or very low residual
enzyme activity and clinically manifested by developmental and neurological delays,
encephalopathy, feeding problems, and a characteristic maple syrup odor in urine.
Disorders branched-chain amino acids
Disorder
name

Amino acid
involved

Enzyme or
transport
defect

Additional biomarkers

MSUD

BCAA (B) high,
allo-Ile (B) high

BCKDC

Plasma ratio of Val:Ile:Leu (3.5:1:2), branch chain
2-ketoacids and 2-hydroxyacids (U)

BCKDC, branched-chain ketoacid dehydrogenase complex.

Table 2.
Laboratory findings in MSUD.

1.4 Urea cycle disorders
During protein catabolism, amino acids’ carbon skeleton is metabolized to
gluconeogenic and/or ketogenic precursors whereas nitrogen group is converted to
ammonia through the deamination process. Toxic ammonia derived from amino
acids and other metabolic sources is entering the urea cycle and further is converted
to the readily excreted and nontoxic urea. The cycle takes place in the liver and a deficiency of any enzymes or transporters involved in the urea cycle can cause ammonia
accumulation (hyperammonemia) which has a highly toxic effect on the central
nervous system. The overall estimated incidence of urea cycle disorders is 1:8000. All
urea cycle disorders have an autosomal recessive inheritance, with the exception of
ornithine-transcarbamylase deficiency (OTCD), which is X-linked. Plasma citrulline
is a key amino acid in the biochemical diagnosis of urea cycle defects (Table 3).
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome
is caused by the mutations in the SLC25A15 or ORNT1 gene which result in the
deficiency of ornithine translocase. The protein transports ornithine, lysine,
and arginine across the inner mitochondrial membrane in peripheral tissues and
pericentral hepatocytes. ORC1 deficiency reduces the availability of mitochondrial
ornithine, which leads to the ornithine increase in the cytosol (hyperornithinemia).
In the liver, since the mitochondrial ornithine is a required substrate for ornithine
transcarbamylase (OTC), the reduced level of mitochondrial ornithine slows down
flux through the urea cycle (Figure 3). As a result of the reduced capacity of the
urea cycle, ammonia and carbamoyl-phosphate levels increase (hyperammonemia).
At the same time, an excess of carbamoyl-phosphate is diverted to react with lysine
to form homocitrulline (homocitrullinuria) or enters in the pyrimidine pathway,
to form orotic acid which is later excreted in urine. Similarly, as for other urea cycle
disorders, early diagnosis in infancy may improve the clinical outcome of HHH.
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Urea cycle disorders
Disorder name

Amino acid
involved

Enzyme or
transport defect

Additional biomarkers

Citrullinimia I

Cit (B) markedly
elevated

ASS

Hyperammonemia,
orotic acid (U), can be
accompanied by high
glutamine and alanine (B)

Citrullinimia II/citrin
deficiency

Cit (B) moderate
high, Met, Lys (B)

Asp/Glu
mitochondrial
exchanger

Hyperammonemia, orotic
acid (U). Citrulline is
moderately elevated

CPS-I deficiency

Cit (B) low

CPS1

Can be accompanied
by high glutamine and
alanine (B)

Ornithine
transcarbamylase
deficiency

Cit (B) low

OTC

Nonspecific amino
acid profile: increased
glutamine, alanine and
decreased ornithine,
arginine (B). Orotic acid
(U) markedly increased

Arginino-succinic
acidemia

ASA (B), (U)
elevated

ASL

Low citrulline, low
arginine (B)

Argininemia

Arg (B) high

Arginase

Orotic acid (U), Normal or
reduced citrulline (B)

HHH

Orn (B, U), high

ORC1

Homocitrulline (U) high

Co-factor producing
N-acetyl glutamate
synthetase deficiency

Gln (B) high

NAGS

Cit (B) low, alanine high
(B)

B, blood; U, urine.

Table 3.
Laboratory findings in urea cycle disorders.

Figure 3.
Urea cycle. ARG, arginase; ASS, argininosuccinate synthase; ASL, argininosuccinate lyase; CPS1,
carbamoylphosphate I synthase; ORNT 1, mitochondrial ornithine transporter; OTC, ornithine
transcarbamylase.
5
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1.5 Disorders of sulfur amino acids metabolism
Homocystinuria is a disorder of methionine metabolism (Figure 4). The main
biochemical finding in homocystinuria is accumulation of a sulfur-containing
amino acid homocysteine and its metabolites in the blood and urine. Homocysteine
is formed from methionine via transmethylation. Once generated homocysteine can
be irreversibly degraded via transsulfuration pathway to cysteine or remethylated
back to methionine by methionine synthase. Remethylation involves a transfer of
methyl group from 5-methyltetrahydrofolate to homocysteine via cobalamin (Cbl)dependent methionine synthase (MT) and links folate cycle and homocysteine
pathway. Homocysteine can also be remethylated through an additional pathway
which involves liver and kidney betaine-homocysteine methyltransferase. Defects
in any of these steps can result in homocystinuria. The classic homocystinuria is
caused by cystathionine β-synthase (CBS) deficiency [10], a key enzyme in the
trans-sulfuration pathway that converts homocysteine into cystathionine. A block
at cystathionine β-synthase limits transsulfuration to the cysteine and results
in both increased homocysteine and methionine, the latter caused by enhanced
remethylation. The remethylation homocystinuria disorders include methylenetetrahydrofolate reductase deficiency (MTHFR) and defects of cobalamin (Cbl)
metabolism [11]. It has to be noted that methionine and not homocysteine is
analyzed through the newborn screening, thus, MTHFR disorder and the cobalamin defects may not be detected because methionine level in these disorders can be
normal. To increase the detection rate in cobalamin related disorders and MTHFR,
some studies report a benefit of adding total homocysteine analysis to the diagnostic workflow [12]. Total homocysteine is defined as the sum of all homocysteine
species in plasma/serum, including free and protein-bound forms. The measurement of total homocysteine requires an immediate separation and freezing of the
collected plasma.

Figure 4.
Sulfur amino acids metabolism. CBS, cystathionine β synthase; Cbl, cobalamin; SAM, S-adenosyl methionine;
SAH, S-adenosylhomocysteine; MAT, methionine adenosyltransferase; MS, methionine synthase; MTHFR,
methylene tetrahydrofolate reductase; THF, tetrahydrofolate.
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Disorders of sulfur amino acids
Disorder name

Amino acid
involved

Enzyme or
transport
defect

Additional biomarkers

Homocystenuria

Free
homocystine
(B, U) high

CBS

Total Hcy and methionine (B, U)

S-Adenosylhomocysteinehydroxylase deficiency

Met (B) high

AdoHcyas

Mildly elevated total plasma Hcy,
S-adenosylhomocysteine, (B),
S-adenosylmethionine (B)

Sulfate oxydase
deficiency

SSC* (B, U) high

SUOX

Taurine, low cystine (B, U)

Molybden cofactor
deficiency

SSC* (B, U) high

SUOX,
XDH, AO

Taurine, low cystine (B, U), elevated
hypoxanthine and xanthine (U), low
uric acid (B)

Glycine-Nmethyltransferase
deficiency

Met (B) high

GNMT

S-adenosylmethionine (B)

Hyper-methioninemia

Met (B) high

MAT

CBS, cystathionine beta synthase; AdoHcyas, S-adenosylhomocysteine hydroxylase; SUOX, sulfate oxidase; XDH,
xanthine dehydrogenase; AO, aldehyde oxidase; GNMT, glycine-N-methyltransferase.
*
S-sulphocysteine may not be detectable in plasma using routine methods in sulfite oxidase and molybdenum co-factor
deficiencies.

Table 4.
Laboratory findings in disorders of sulfur amino acids.

1.6 Nonketotic hyperglycemia
Nonketotic hyperglycemia (NKH) is a severe disorder of glycine metabolism.
Glycine is catabolized through the four-peptide cleavage complex. P-protein, a
pyridoxal phosphate-containing protein, T-protein, a protein required for the
tetrahydrofolate-dependent reaction, H-protein, a protein that carries the aminomethyl intermediate and then hydrogen through the prosthetic lipoyl moiety, and
L-protein, a lipoamide dehydrogenase. The disorder is so severe, that most of the
affected individuals die within few months of life or survive with significant intellectual disabilities. Main laboratory findings in NKH is plasma and CSF elevated glycine.

Disorders of amino acids transport
Disorder name

Amino acid
involved

Enzyme/transport defect

Additional biomarkers

Cystinuria

Cystine (U)
elevated

Cystine and dibasic amino acids
in GI tract and renal tubule

Lysine, ornithine, arginine
increase (U)

Lysinuric protein
intolerance

Lys (U)
markedly
elevated

Cationic amino acids
transporter SLC7A7

Arginine, ornithine
moderate increase (U),
orotic acid (U)

Fanconi
syndrome

All amino acids
elevated (U)

Defects in proximal renal tubule

U, urine.

Table 5.
Laboratory findings in renal aminoacidurias.
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Disorder of glycine metabolism
Disorder name

Amino acid
involved

Enzyme/transport defect

Additional biomarkers

Nonketotic hyperglycemia
(NKH)

Gly (B,
CSF) high

Mutations in Gly cleavage
system

Increased CSF/plasma
Gly ratio

B, blood; CSF, cerebrospinal fluid.

Table 6.
Laboratory findings in NKH.

1.7 Renal aminoacidurias
Renal aminoacidurias are disorders have inherited defects that affect renal
tubular reabsorption process. Thus these disorders are characterized by abnormal
urinary amino acids.

2. Newborn screening
Early diagnosis may prevent serious implications of inborn errors of metabolism,
including amino acids disorders and significantly decrease morbidity and mortality.
Newborn screening is a public health program that facilities early diagnosis by identifying neonates with potential treatable inborn errors of metabolism at the very early
stages of their lives [13, 14]. This practice helps to manage the disease even for neonates
that do not have evident symptoms in the first days of their lives. Amino acids analysis
has always been an important part of the newborn screening. The first PKU screening
bacterial inhibition assay was invented by Robert Guthrie in the early '60s [15]. Since
that time, screening for IEMs is performed worldwide. In the United States, newborn
screening is a state-mandated public health program ensuring that all newborns are
screened for certain inherited conditions at birth. The panel of screening conditions
varies from state to state. The advisory committee on heritable disorders in newborns
and children advises the Secretary of Health and human services uniform screening
panel, which currently consist of 34 core disorders and 26 secondary disorders. The
recommended panel includes multiple amino acids related disorders (Table 7).
Recommended
uniform screening
panel (RUSP)

Argininosuccinate aciduria, citrullinemia type I homocystinuria
(cystathionine-β-synthase), maple syrup urine disease, phenylketonuria/
hyperphenylalaninemia, tyrosinemia I

Additional nonRUSP conditions

Nonketotic hyperglycinemia (NKH), prolinemia, hyperammonemia/ornithinemia/
citrullinemia (HHH)

Secondary

Defects of biopterin cofactor biosynthesis and regeneration, citrullinemia II,
hypermethioninemia, tyrosinemia II, tyrosinemia III

Table 7.
List of amino acids disorders that are recommended by the Secretary of the Department of Health and Human
Services (HHS) as a part of state universal newborn screening (NBS) program effective July 2018.

3. Quantitative amino acids analysis
Quantitative amino acids analysis is an important tool for diagnosis of amino acids
disorders and nutritional monitoring of individuals with already established diagnosis. Amino acids can be detected in most biological fluids, however, the most common
8
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fluids for inborn errors of metabolism diagnostics and monitoring are blood, plasma,
and urine. In some cases, cerebrospinal fluid (CSF) amino acid levels are also diagnostic (Table 5). Although each disorder is biochemically characterized by abnormal
levels of a single or a few amino acids, quantitative a non-screening analysis, and
interpretation is not restricted to those metabolites and consist from a panel of nearly
40 amino acids and specific ratios. For example, along with plasma phenylalanine
level, it is important also to assess plasma phenylalanine/tyrosine ratio that can be
used to differentiate between PKU and non-PKU hyperphenylalaninemia [16].
3.1 Factors affecting amino acid analysis
The different chemical characteristics, a wide range of normal physiological
levels [17–19], age groups variability and other factors detailed below represent a
significant analytical challenge for the amino acid analysis. Diet is one of the
significant factors that can highly affect amino acids levels [20, 21]. For example,
meat and poultry consumption leads to increased excretion of β alanine and
1-methylhistidine. Thus blood collection intended for amino acids analysis is
recommended after overnight fasting. Other factors such as urinary bacterial
contamination can significantly alter urinary amino acids profile [22]. Some drugs
interfere with amino acids metabolism [23] or cause signal artifacts. Valproic acid,
for example, can cause an increase in plasma glycine. Anticoagulants used during sample collection also can contain interfering constituents [24]. For example,
blood collection tubes containing sodium bisulfate in addition to heparin can
yield a peak of S-sulfocysteine, falsely suggesting sulfite oxidase deficiency.
Ethylenediaminetetraacetic acid (EDTA) additive in collection tube can produce
ninhydrin-positive peaks, therefore lithium-heparin coated tubes are strongly
preferred for the blood collection. An additional interfering factor to the amino acid
analysis is a hemolysis as it may lead to the decrease of arginine with simultaneous
increase of ornithine due to red blood cells arginase activity, and an increase in
taurine that released from leukocytes and platelets. Serum is usually not a choice for
the amino acids analysis, because blood needs to clot at room temperature during
which asparagine is converted to aspartic acid and glutamine to glutamic acid.
For the urine analysis, a 24-h urine collection is preferred, alternatively, an
overnight collection can be sufficient for the diagnostic purposes. In order to avoid
artifacts, no preservatives are added to the urine sample.
Overall, during a prolong sample storage glutamine and asparagine decrease
whereas glutamic and aspartic acids increase simultaneously. Additional markers
of prolong storage are an increase of ethanolamine derived from phosphoethanolamine decomposition, increased tryptophan, GABA and taurine.
When cerebrospinal fluid is used for the analysis, it must be not contaminated
with blood, as it leads to the nonspecific increase of multiple amino acids and can
mask diagnostic findings.
Quantitative amino acids analysis implies in a variety of nonclinical fields such
as biomedical research, bioengineering, food science, and agriculture. Multiple
analytical methods have been developed over the years, however, some of these
methods are not cost effective and labor intensive and thus are not applicable in
clinical settings. The aim of next paragraphs is to describe the most common and
widely used platforms in laboratory medicine field.
3.2 Ion exchange chromatography coupled with optical detection
In early 50s, diagnostic quantitative amino acid analysis became feasible with
Moore and Stein publication on plasma amino acids separation with polystyrene
9
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resin column [25] and the subsequent automatization of the technique [26].
The principle, called ion exchange chromatography (IEC) with a post-column
derivatization, for a long time remained a gold standard for the clinical amino
acids analysis. Nowadays, despite the methodological advancements, the ion
exchange chromatography using a lithium buffer system, followed the post-column
derivatization with ninhydrin and UV detection is still widely used in clinical
setting.
Standard sample preparation for IEC amino acid analysis involves deproteinization with 35% (w/v) sulfosalicylic acid (SSA) added to the biological fluid. It is
recommended to use one volume of SSA to 10 volumes of plasma. A fixed amount
of non-physiological amino acid as an internal standard is added to all samples.
Commonly used internal standards are d-glucosaminic acid, S-2-aminoethyl1-cysteine, norvaline, and norleucine, however, norleucine can interfere with
argininosuccinic acid peak. After a short incubation, centrifugation and filtration,
the sample is ready for the injection and separation.
In IEC, the separation is driven by the ionic interactions between the amino acid
and functional ligands linked to the stationary phase of the column. The chromatographic column is filled with negatively charged resins. The sample is loaded on the
column in low acidic pH and at this point, all amino acids bear a positive charge and
strongly interact with the column. Manipulation with a lithium buffer composition
during the run alters pH and salt composition, and as a result, there is a change in
amino acid charge status (Figure 5). As the isoelectric point is reached amino acid is
not charged anymore and has weak interactions with the charged column.
The complex separation of multiple amino acids is achieved based on ionic
interactions strength. Amino acids with the weakest ionic interactions to the
column start to elute first. After column elution, amino acids are mixed with a
post-column reagent and are optically detected. The most common and wellestablished post-column derivatization is reaction with ninhydrin that produces a
purple Ruhemann’s chromophore (λmax = 570 nm, Figure 6) for α-amino acids and
yellow product with secondary amines (λmax = 440 nm) for such as proline and
hydroxyproline [27].
The absorbance intensity of the produced colorful analyte originated from
every eluted amino acid is proportional to the amino acid’s concentration in
the examined biological fluid. Despite the fact that IEC amino acids technique
is highly reproducible with a good linearity over a broad range, it suffers from
a long run time for the full amino acids profile (about 150 min), and a lack
of specificity as amino acids identification is based solely on retention time.
Furthermore, co-elution of some amino acids on standard IEC method is

Figure 5.
Aspartic acid charge in different pH.
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Figure 6.
Ninhydrin reaction with amino acid to produce Ruhemann’s purple.

observed. For example, homocitrulline co-elutes with methionine and make
challenging HHH syndrome. Moreover, allo-isoleucine, a diagnostic market for
MSUD co-elutes with cystathionine. Argininosuccinic acid that accumulates in
patients with argininosuccinate lyase deficiency has the same retention time as
leucine. Additional drawback of the methodology is a limited stability of ninhydrin (recommended storage of the working solution ≤1 month) which adds up to
the cost of the analysis.
3.3 RP-HPLC and RP-UPLC techniques
In recent years, reverse-phase high-performance liquid chromatography
(RP-HPLC) and ultra-high performance liquid chromatography (UPLC) methods emerged as an alternative to the ion exchange chromatography. In RP-HPLC
methods, the separation is based on hydrophobic interactions between the
analyzed amino acid in the mobile phase and the immobilized hydrophobic
ligands attached to the nonpolar column stationary phase. RP-HPLC offers
a great resolution of very closely related molecules under a wide range of
chromatographic conditions. For the optical detection, derivatization with
o-phthalaldehyde (OPA) can be used as a pre-column or a post-column reaction.
During the reaction, in the presence of thiol such as 2-mercaptoethanol, a stable
fluorescent product is produced and can be detected by fluorimetry (excitation
340 nm and emission 410 nm) or UV (340 nm) [28, 29]. Although reproducible
and automated [30], OPA derivatization method is not a good choice for proline/hydroxyproline and sulfur-containing amino acids detection. Alternative
reagents for RP-HPLC with pre-column derivatization are phenylisothiocyanate
(PITC, Pico-Tag commercialized by Waters) [31], dimethylamino-azobenzenesulfonyl-chloride (DABS-Cl) [32] and 9-fluorenylmethylchloroformate
(FMOC-Cl) [33].
More advanced UPLC systems employ a small particle size (typically 1.7 μM) and
a high pH range stable columns. These systems use less solvent and are operated in a
high pressure which allows an excellent resolution achieved in a short time frame and
thus potentially decreases turnaround time per sample. Narayan et al. analyzed 170
patient samples by pre-column 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate
(AQC) derivatization (Figure 7) followed by reverse phase UPLC [34] and compared amino acids data to the traditional amino acids analyzer operated through ion

Figure 7.
AQC reaction with amino acid.
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exchange chromatography method. The study found that UPLC method is comparable to the reference IEC and thus adaptable to the clinical laboratory.
Peake et al. developed a modified RP-UPLC method and achieved a better resolution for tyrosine, glycine, arginine and homocitrulline peaks [35]. The improved
method also provides enhanced resolution to separate ornithine from mesocystathionine. There is a high clinical significance to accurate ornithine analysis as
ornithine’s levels are diagnostic for hyperornithinemia-hyperammonemiahomocitrullinemia (HHH) syndrome. The developed UPLC method has several
advantages. Due to the short analysis time, it is feasible to include calibration
prior to the analysis of urgent samples with a special turnaround times. Overall,
RP-UPLC decreases turnaround time per sample, however, commercial kit components have a very limited shelf life and thus the method is not cost effective for
clinical laboratories with a small samples volume.
Overall, ion exchange chromatography, RP-HPLC, and RP-UPLC techniques
have a good reproducibility and a high sensitivity in the low picomole range, however, they all are carried out with optical detection. The main drawback of this type
of detection is a lack of specificity as amino acids identification is solely based on
the retention time. This can potentially cause to the false findings. For example, in a
standard ion exchange chromatography method, ampicillin and amoxicillin co-elute
with phenylalanine and it can be reported as falsely elevated.
3.4 Flow infusion tandem mass spectrometry (FIA-MS/MS)
More recently, developments and advancements in mass spectrometry field
led to the inclusion of tandem mass spectrometry (MS/MS) as an alternative high
throughput and specific technique for the amino acids analysis. It is also feasible
to separate amino acids by liquid chromatography prior to the mass spectrometry
analysis, however, it is time-consuming in clinical settings. Instead, tandem mass
spectrometry scans are used for the high throughput, cost-effective amino acids
analysis. It has to be noted, that FIA-MS/MS is a screening analysis that widely
implemented through the newborn screening initiative.
For the newborn screening, blood samples are typically collected on filter paper
and a defined size (typically 3 mm) disks are punched out of the paper and are
extracted. The early assays required derivatization by butylation (Figure 8) in order
to improve detection limits and minimize ion suppression effects in a complex biological matrix. Currently, to increase a throughput, some clinical laboratories skip
on the derivatization step. Extracted and derivatized samples are directly introduced by injection to the mass spectrometer instrument with no chromatographic
separation. Usually, 5–10 μl of a sample is injected into a flowing solvent at a very
low (20–50 μl) flow rate. All screened amino acids (Table 8) are eluting at the same
time whereas a typical run time is 1.5–2 min per sample. Every analyzed amino acid
is assayed with the corresponding stable isotopic labeled standard.
The isotopic-labeled standards are closely related to the structure of the analyzed amino acids and have similar physicochemical properties to the target amino
acids, but can be distinguished by mass spectrometry as they have a different

Figure 8.
Derivatization of alanine with n-butanol.
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Target amino acid

m/z

Alanine

146.1

Arginine

231.2

Aspartic acid

246.2

Citrulline

232.2

Glutamic acid

260.2

Glycine

132.1

Leucine/isoleucine

188.2

Methionine

206.2

Ornithine

189.2

Phenylalanine

222.2

Tyrosine

238.2

Valine

174.2

Internal standard
2

m/z

H4 alanine

150.1

13

C,2H4 arginine

236.2

2

H3 aspartic acid

249.2

2

H2 citrulline

234.2

H3 glutamic acid

263.2

2

15

N,13C glycine
2

134.1

h3 leucine

191.2

H3 methionine

209.2

2

H2 ornithine

191.2

C6 phenylalanine

228.2

2

13

13

C6 tyrosine

244.2

2

182.2

H8 valine

Table 8.
Amino acids analyzed by FIA-MS/MS for the standard newborn screening panel and their stable isotopic
labeled internal standards.

mass to charge ratio (m/z) (Table 8). They are added at a known quantity, and the
response of each analyzed amino acid is normalized by the response of the matching internal standard. This type of normalization reduces a systematic error due to
the poor recovery and decreases multiple matrix effects. The inclusion of internal
standards also corrects a batch to batch variability due to the sample preparation
and overall raises the accuracy and precision of the assay.
The tandem mass spectrometer has five basic components: the ion source
where all molecules are a subject to the soft ionization, a mass analyzer that
separates analytes based on their mass to charge ratio (Q1), a collision cell where
molecular ions encounter an inert gas and undergo fragmentation (Q2), a second
mass analyzer to separate fragments produced in the collision cell (Q3), and a
detector. In collision cell, most of the screened butylated α-amino acids form a
common and a very specific fragment of 102 Da (Figure 9). The tandem mass
spectrometer then can be set to scan a constant mass difference of 102 Da and to
produce a spectrum of the molecular ions derived from those amino acids that lost
102 Da in the collision cell (Q2) (Figure 9). Butylated amino acids with a basic
side chains such as ornithine, citrulline loose ammonia and butyl formate in the

Figure 9.
Schematic presentation of tandem mass spectrometer. Phenylalanine (as butyl ester) looses 106 Da in the
collision cell. When mass spectrometer operates in neutral loss scanning mode, it scans Q1 and Q3 in a
synchronized manner. The mass difference of 102 Da (corresponds to a neutral fragment common to the most
amino acids) passing through Q2 remains constant.
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Figure 10.
Sulfur amino acids and their disulfides.

collision cell (m/z 119). For glycine and arginine, the most intensive signal corresponds to the loss of 56 and 161 Da, respectively. All these specific losses or transitions can be detected by different and highly specific tandem mass spectrometer’s
scans in the single analysis.
The main limitation of the FIA-MS/MS is inability to differentiate amino acids
that share the same m/z such as leucine/isoleucine and hydroxyproline (butylated
derivatives m/z 188), alanine/sarcosine (butylated derivatives m/z 146) and in a
more extended profiles glutamine/lysine (butylated derivatives m/z 186), proline/
asparagine (butylated derivatives m/z 172). Also, FIA-MS/MS is not applicable
for cysteine and homocysteine analysis since these amino acids are not stable and
react to form cystine and homocystine (Figure 10). During the ionization process,
cystine and homocystine produce double charged molecules and it complicates the
analysis.
Due to the high sensitivity and selectivity, there are more mass spectrometrybased techniques are available for the amino acids analysis, although because of
extensive sample preparation or limited number of amino acids covered, these
methods are not widely used in clinical laboratories. Gas chromatography mass
spectrometry (GCMS) [36], capillary electrophoresis mass spectrometry (CEMS)
[37], ion pairing (IP)-LC-MS/MS, HILIC-LC-mass spectrometry [38] and two
column LC-MS/MS methods [39], ion pairing (IP)-LC-HRMS (TOF) [40] can be
successfully applied for the physiological amino acids analysis although with some
limitations.

4. Diagnosis of amino acids related disorders
The initial diagnosis of amino acids disorders is based on clinical presentation and
biochemical findings such as abnormal levels of specific amino acids (Tables 1–6)
or accumulation of the downstream metabolites in biological fluids, however, these
characteristics are very heterogenic and often nonspecific. The most common clinical
indications for the quantitative amino acid analysis in neonates and pediatric patients
are coma, lethargy, seizures and vomiting, unexplained developmental delay and siblings with similar symptoms. Plasma amino acids analysis is also ordered as a conformational test to follow up abnormal newborn screening results. Hyperammonemia
is characteristic to the most urea cycle disorders (Table 3) and therefore is another
14
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Figure 11.
Treatment strategies in amino acids disorders.

strong indication for plasma amino acids analysis. Additional general biochemical
indicators of follow up quantitative amino acids analysis are ketosis (high blood
and urine ketones), acidosis (blood pH below 7.35) and lactic acidemia (high lactate
excretion), alkalosis (blood pH above 7.45), polyuria, polydipsia (extreme thirstiness), and dehydration. Amino acids analysis is also an important tool in the diagnosis of muscle and liver diseases, neurological disorders, renal failure, autism spectrum
disorders and nutritional disturbances. Interpretation of amino acids profile is not
just based on the abnormal level of a single amino acid, but rather involves pattern
recognition, diagnostic ratios (Tables 1 and 2) and correlation to the patient’s clinical
history. It is recommended to confirm the diagnosis by molecular analysis or in vitro
enzymatic assay (usually skin or tissue biopsy sample or blood cells).

5. Treatment options
Currently, there are numbers of available therapeutic approaches that aim in
a substrate and downstream products restoration balance (Figure 11). One of the

Figure 12.
Removal of toxic ammonia. In urea cycle disorders ammonia cannot be converted to urea, but alternatively
can be converted to glutamine and glycine. Ammonia scavengers phenylbutyrate and sodium benzoate react
with glutamine and glycine and consequently remove excess of ammonia. Phenylglutamine and hippurate are
excreted in urine.
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approaches in this direction is to reduce substrate accumulation by dietary restrictions. Nutritional therapies restrict offending amino acid or often total protein
consumption through provision and monitoring of all essential components to
meet dietary requirements. For example, special medical foods for PKU affected
individuals have a very negligible amount of phenylalanine, but supplement the
total protein required for the normal growth, development and nutritional status.
Another example is MSUD nutritional management that restricts intake of the
branch chain amino acids [41], but supplies the majority of the protein required in
the standard diet.
Amino acids disorders are often manifested by the accumulation of toxic
downstream metabolites. For example, urea acid disorders are characterized by
life-threatening hyperammonemia (ammonia accumulation). Toxic metabolites
removal treatment aims at reducing production or increasing excretion of these
metabolites. To reduce hyperammonemia, sodium benzoate and phenylbutyrate
are used to increased ammonia excretion (Figure 12) and to bypass the urea cycle
metabolic block [42, 43]. Another example is an approach to reduce the production of succinylacetone, a neurological toxin that accumulates in tyrosinaemia
I. Nitisinone (NTBC) treatment blocks a formation of fumarylacetoacetate and its
subsequent conversion to the succinylacetone [44, 45].
If as a result of mutation, a specific enzyme still retains its residual activity, it
can be stimulated by a co-factor or a co-factor precursor supplementation. This
concept applies in treating tetrahydrobiopterin deficiency (Figure 2) [46, 47],
remethylation defects (Figure 4) [48] and cystathionine beta-synthase deficiency
(Figure 4) [10]. In some amino acids disorders, even partial metabolic block
prevents from synthesizing an essential downstream metabolite to meet metabolic
requirements. In these cases, essential product supplementation is required. For
example, as a part of urea cycle disorders management, l-arginine and l-citrulline
are administered [43]. This helps to reduce excessive protein catabolism, due to the
low arginine levels.

6. Conclusion
In conclusion, amino acids disorders are a group of inborn errors of metabolism
with highly variable clinical and biochemical presentations. Clinical manifestation
often comprises severe neurological symptoms, growth and developmental delays.
Most of the amino acids disorders related conditions are included in the newborn
screening program to facilitate early diagnosis and early disease treatment. The
analysis of physiological amino acids levels is a key tool in the diagnosis and clinical
management of inborn errors of amino acids metabolism. A small subset of amino
acids is analyzed in newborn screening by tandem mass spectrometry and leads to
the detection of affected neonates even when they do not have a symptomatic disease manifestation. A more comprehensive, quantitative amino acids analysis covers
analysis of nearly 40 amino acids. Prior to the analysis and results interpretation,
pre-analytical variables such as a fasting status and medication treatments should
be taken into account in order to avoid false reported findings. A most common
sample preparation method for the quantitative amino acids analysis is acidification
of specimen with a known small volume of concentrated acid, such as sulfosalicylic acid to precipitate proteins and large molecules, followed by centrifugation,
leaving the water-soluble amino acids in the supernatant for the analysis. A variety
of analytical methods have been developed over the past 60 years, and scientists
have made significant achievements in the fields of derivatization, chromatography
and mass spectrometry, however, the ion exchange chromatography method still
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remains the gold standard technique in the field. It is expected that more advanced
techniques will be developed targeting important clinical laboratories requirements
such as reduced samples pretreatment, linearity over the large concentration range
for over the 40 amino acids, increased automation, high sensitivity, shorter run
time and improved specificity. These methodological improvements will facilitate
the diagnostic process and therapy monitoring for amino acids disorders. The
field is also expending to the more exploratory platforms such as a whole-genome
sequencing and untargeted metabolomics. Although these modalities have some
restrictions in clinical settings [1, 49], they facilitate novel genes identification,
novel biomarkers discovery and disease associations and thus strongly advancing
the field [50, 51].
The major treatment goal for amino acids disorders is to normalize imbalance
between the substrate and its downstream products and to avoid accumulation of
the toxic substances. At the same time, nutritional management must meet basic
dietary requirements for growth and normal development. Even though for many
amino acids disorders current treatments do not offer a cure, they significantly
improve the quality of life. It is expected over the upcoming years, that methodological advances will lead to a greater understanding of the IEM and in particular
amino acids related disorders which will help further to improve disease outcomes.
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